AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04591301
Drug: HEC113995 PA•H2O tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each dose of HEC113995 PA•H2O tablets will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.
Trial: NCT04591301
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.
Trial: NCT00725829
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 40mg/d
Trial: NCT00725829
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00996372
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will be randomized to flibanserin or placebo in a double-blind manner
Trial: NCT02422121
Drug: RNS60
RxNorm normalized name: Ronasin 60
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02422121
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01085279
Drug: Modified Kligman's formula (Triple topical therapy)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroquinone 5%, tretinoin 0.05%, triamcinolone acetonide 0.1% once a day during 15 weeks
Trial: NCT03167775
Drug: Elemene Injection/Elemene Oral Emulusion
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01777776
Drug: LEE011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEE011 will be administered orally, once daily for 21 consecutive days followed by a 7-day planned break (28-day cycle).
Trial: NCT01777776
Drug: LGX818
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LGX818 will be administered orally, once daily on a continuous dosing schedule (28-day cycle).
Trial: NCT00650845
Drug: Dotarem®-enhanced MRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV administration before MRI exam
Trial: NCT01859312
Drug: Hydrocortisone (Solucortef)
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Continuous subcutaneous hydrocortisone infusion (CSHI) via Medtronic insulin pump (MMT-722NA). Total daily hydrocortisone dose was calculated based on the patient's estimated cortisol clearance. Rates were established to achieve peak and trough concentrations within the normal circadian cortisol range.
Trial: NCT02046616
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate dosing is not specified by the protocol and will be given as per standard practice. Participants must be at a stable dose that was initiated at least 4 weeks prior to baseline.
Trial: NCT02046616
Drug: Non-Biologic DMARDs
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive non-biologic DMARDs (same non-biologic DMARD that participant was receiving at time of study entry). Dosing is not specified by the protocol and will be given as per standard practice. Participants must be at a stable dose that was initiated at least 4 weeks prior to baseline.
Trial: NCT00791752
Drug: AZD4017
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ascending single doses (start dose 2 mg), oral suspension
Trial: NCT00791752
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03944512
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg Pravastatin taken daily
Trial: NCT00389129
Drug: acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00680472
Drug: HKT-500 Ketoprofen Topical Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HKT-500 Ketoprofen Topical Patch
Trial: NCT00671476
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02945267
Drug: Placebo plus S1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: 400 mg/w, Intravenous infusion, Infusion time ≥ 60 min, d1, once every two weeks;S1: 40 mg (Body surface area\<1.5 m2) or 60 mg (Body surface area\>1.5 m2) ,oral,d1-d14, every three weeks for a cycle
Trial: NCT03803449
Drug: 50ug fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: participants in fentanyl group are given intervention regimen: 50ug fentanyl.
Trial: NCT01156116
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral placebo tablet
Trial: NCT00843193
Drug: INTRAVENOUS GSK679586
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK679586 will be provided as a clear or colorless to pale yellow liquid with the unit dose strength of 10mg/kg and will be infused over an hour. The infusion will be delivered by a programmable infusion pump
Trial: NCT00843193
Drug: INTRAVENOUS PLACEBO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clear or colorless 0.9% sodium chloride saline solution will be infused over an hour. The infusion will be delivered by a programmable infusion pump
Trial: NCT01975376
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
Trial: NCT00927212
Drug: AS101 ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily topical application
Trial: NCT00932321
Drug: Norethindrone Acetate/Ethinyl Estradiol 24 Days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet per day for 24 days of each 28 day cycle followed by 4 placebo tablets
Trial: NCT00932321
Drug: Norethindrone Acetate /Ethinyl Estradiol 21 Days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet per day for 21 days of each 28 day cycle followed by 7 placebo tablets
Trial: NCT02775916
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03057015
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in the placebo group.
Trial: NCT03057015
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine or Placebo added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in both treatment and placebo groups.
Trial: NCT02623699
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT01469273
Drug: Mutaflor® Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of Mutaflor-Suspension on 10 consecutive days.
Trial: NCT03114020
Drug: Placebo Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice a day 3 ml of placebo inhalation solution
Trial: NCT01119950
Drug: NVA237 12.5 µg once daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NVA237 12.5 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
Trial: NCT01119950
Drug: NVA237 25.0 µg once daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NVA237 25.0 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
Trial: NCT01119950
Drug: NVA237 12.5 µg twice daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NVA237 12.5 µg via dry powder inhaler twice daily for 28 days during either period 1 or during period 2.
Trial: NCT01119950
Drug: NVA237 50.0 µg once daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NVA237 50.0 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
Trial: NCT01119950
Drug: NVA237 25.0 µg twice daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NVA237 25.0 µg via dry powder inhaler twice daily for 28 days during either period 1 or during period 2.
Trial: NCT01119950
Drug: NVA237 100.0 µg once daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NVA237 100.0 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
Trial: NCT01119950
Drug: NVA237 50.0 µg twice daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NVA237 50.0 µg via dry powder inhaler twice daily for 28 days during either period 1 or during period 2.
Trial: NCT01119950
Drug: Placebo to NVA237 once daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to NVA237 via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
Trial: NCT01675518
Drug: ASP7991
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01675518
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00479336
Drug: OPC-41061 7.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5mg, 1 tablet a day
Trial: NCT00479336
Drug: OPC-41061 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, 1 tablet a day
Trial: NCT00479336
Drug: OPC-41061 15mg
RxNorm normalized name: naphazoline hydrochloride 0.27 MG/ML / pheniramine maleate 3.15 MG/ML [Opcon-A]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15mg, 1 tablet a day
Trial: NCT02655380
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After anesthesia induction with ketamine, predetermined remifentanil using Dixon's up and dowm method is administered.
Trial: NCT00362206
Drug: Fenofibrate/Simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Fenofibrate and Simvastatin 20mg
Trial: NCT00362206
Drug: Fenofibrate/Simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Fenofibrate and Simvastatin 40 mg
Trial: NCT00362206
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pravastatin 40 mg
Trial: NCT00057382
Drug: T138067 intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00057382
Drug: doxorubicin intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00541697
Drug: MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 6 Weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00345202
Drug: HMG-CoA reductase inhibition (atorvastatin)
RxNorm normalized name: HMG CoA reductase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00762463
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: capsule, 200 mg QD, 6-12 weeks
Trial: NCT03355846
Drug: Proctocella
FDA approved: no
EMA approved: no
PMDA approved: no
Description: after hygiene treatment for 4 weeks;
Trial: NCT03355846
Drug: Flavonil® cps
FDA approved: no
EMA approved: no
PMDA approved: no
Description: after meals twice a day for 15 days
Trial: NCT03355846
Drug: Flavonil® Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment for 4 weeks;~.
Trial: NCT03038295
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral/eye drop placebo will be taken in enrolled newborns. Other treatment will follow the standard treatment schedule of Early Treatment For Retinopathy Of Prematurity Cooperative Group.
Trial: NCT02610582
Drug: rAAV.hCNGA3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single subretinal injection of rAAV.hCNGA3
Trial: NCT01568749
Drug: Paracetamol formulation 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol
Trial: NCT02930343
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate, a structural analogue of folic acid, can be administered orally or parenterally to treat a variety of rheumatic diseases
Trial: NCT02930343
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low dose prednisolone (weeks 1-2: 7.5 mg/day, weeks 2-4: 5 mg/day, weeks 4-6: 5 mg on alternate day and then stop)
Trial: NCT02930343
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid is to be given to all patients receiving methotrexate at a dose of 5 mg twice a week.
Trial: NCT01552018
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 1 tablet per day for 3 months.
Trial: NCT01951560
Drug: Isotonic saline solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: By infusion over 1 hour
Trial: NCT03721432
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral capsule given 60 minutes prior to epidural anesthesia
Trial: NCT03015974
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03015974
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03015974
Drug: ACE Inhibitor or Angiotensin receptor antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05395949
Drug: conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 30 mg/day, supplemented with calcium and omeprazole, and Prednisone were slowly reduced to 10 mg/day after symptoms were relieved, and combined with 7.5 mg/week MTX therapy.
Trial: NCT01137799
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily (single dose)
Trial: NCT02186574
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01702558
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine will be administered at de-escalating doses (starting from 750 mg/m\^2) to determine the MTD.
Trial: NCT01702558
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine will be administered at the MTD determined in Cohort 1.
Trial: NCT00962637
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule daily
Trial: NCT03400826
Drug: Simvastatin 40mg
RxNorm normalized name: SIMVASTATIN 40MG TAB
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The Treatment Group subjects will orally intake encapsulated Simvastatin 40 mg tablets daily for the 12 weeks duration with water in the evening.
Trial: NCT03400826
Drug: Placebo 40 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Placebo group will orally intake encapsulated Starch 1500, 40 mg Placebo for 12 weeks duration with water in the evening.
Trial: NCT00335400
Drug: Anesthetic Dilating Gel
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02533908
Drug: Fentanyl intranasal
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: fentanyl is applied intranasally with a MAD (mucosal atomization device) prior to the application of nitrous oxide 70% analgosedation
Trial: NCT02533908
Drug: NaCl 0.9% intranasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is applied intranasally with a MAD (mucosal atomization device) Prior to the application of nitrous oxide 70% analgosedation
Trial: NCT00981682
Drug: SER120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once a day treatment of nocturia
Trial: NCT01922739
Drug: Hydrocodone ER
RxNorm normalized name: hydrocodone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants were instructed to take hydrocodone ER tablets orally with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating.
Trial: NCT02575235
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group takes the placebo for the same period.
Trial: NCT01922739
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the double-blind titration period used in the original protocol, placebo tablets matching each dose of hydrocodone bitartrate ER tablets (active drug) were used to maintain the blind but not for purposes of comparison.
Trial: NCT01526317
Drug: Crestor 10mg(Rosuvastatin 10mg), Glucodown OR SR 750mg(Metformin SR 750mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For co-administration,Crestor 1 tablet and Glucodown 1 tablet a day for 5 day.(1 period) For separate administration, Crestor 1 tablet a day for 5 day and Glucodown 1 tablet a day for 5 day.
Trial: NCT03299452
Drug: Non Chemotherapy
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines.
Trial: NCT00755495
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramelteon placebo-matching tablets, orally, once daily and doxepin placebo-matching liquid, orally, once daily for up to five weeks.
Trial: NCT02518971
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one capsule daily
Trial: NCT02346175
Drug: SHR3824
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02346175
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01440088
Drug: TH-302 in Combination with Doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg/m2 of TH-302 will be administered by IV infusion over 30-60 minutes on Days 1 and 8 of a 21-day cycle.~Doxorubicin may be delivered as a bolus administration or as a continuous infusion administration; administration schedule must be specified prior to enrollment.~Doxorubicin bolus administration: 75 mg/m2 administered by bolus injection starting on Day 1 of a 21-day cycle.~Doxorubicin continuous administration: 75 mg/m2 administered by continuous IV infusion over 48-96 hours starting on Day 1 of a 21-day cycle.~Doxorubicin administration will start between 2 to 4 hours after completion of the TH-302 infusion when used in combination with TH-302.
Trial: NCT01440088
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin may be delivered as a bolus administration or as a continuous infusion administration; administration schedule must be specified prior to enrollment.~Doxorubicin bolus administration: 75 mg/m2 administered by bolus injection starting on Day 1 of a 21-day cycle.~Doxorubicin continuous administration: 75 mg/m2 administered by continuous IV infusion over 48-96 hours starting on Day 1 of a 21-day cycle.
Trial: NCT03299452
Drug: Chemotherapy and target therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines.
Trial: NCT03299452
Drug: Chinese herb medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines.
Trial: NCT01616069
Drug: epinephrine and levosimendan
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epinephrine (0,06mcg/kg/min), levosimendan (0,2 mcg/kg/min)
Trial: NCT01978496
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT03263273
Drug: 1% Topical Minocycline Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treating Papulopustular Rosacea while monitoring for safety and efficacy of the active intervention
Trial: NCT03263273
Drug: 3% Topical Minocycline Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treating Papulopustular Rosacea while monitoring for safety and efficacy of the active intervention
Trial: NCT00344019
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo pre-PCI for ACS
Trial: NCT01648140
Drug: GSK2336805 60 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg tablet, round, 10-mm diameter, white to off-white, no markings
Trial: NCT00880906
Drug: Steroid and Proton Pump Inhibitor Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01377623
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fifty six subjects (28 in each arm) will be enrolled. Subjects undergoing one or two level spinal fusion surgery will be screened for eligibility to participate in the study. Subject will be screened, recruited and randomized during the preadmission visit or the day of surgery. Eligible subjects will be randomized to one of the two treatment group in1:1 ratio to receive either DEX or matching placebo (PBO, LR).
Trial: NCT02725268
Drug: MLN1117
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MLN1117 capsules.
Trial: NCT00668772
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Inhalation Powder, hard PE capsule / hard gelatine capsule
Trial: NCT04252131
Drug: cassia seed tablet
RxNorm normalized name: Padang cassia oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: traditional Chinese herbs
Trial: NCT03351517
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A matching placebo will be given to the patients undergoing total knee replacement surgery on spinal anesthesia to evaluate its efficacy in the management of post-operative pain.